Research
Hormonal
Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.
Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.
StrongSupportsmedium confidence
From baseline to week 52, the least square (LS) mean predicted T2D risk changed from 4.9% to 1.0% for tirzepatide 15 mg.
Why this rating
Based on the randomized controlled trial design of the SURMOUNT-CN trial.
Source
Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trial
Lin Zhao et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16439
other · n=169Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →